The FGF family: biology, pathophysiology and therapy

被引：1511

作者：

Beenken, Andrew ^{[1
]}

Mohammadi, Moosa ^{[1
]}

机构：

[1] NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2009年 / 8卷 / 03期

关键词：

FIBROBLAST-GROWTH-FACTOR; BILE-ACID SYNTHESIS; DOMINANT HYPOPHOSPHATEMIC RICKETS; ENDOTHELIAL-CELL PROLIFERATION; ACTIVATED-RECEPTOR-GAMMA; CHRONIC KIDNEY-DISEASE; SPINAL-CORD REPAIR; PHASE-II TRIAL; AUTOSOMAL-DOMINANT; MULTIPLE-MYELOMA;

D O I：

10.1038/nrd2792

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacological potential of this family. This Review discusses traditional applications of recombinant FGFs and small-molecule FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphataemic diseases.

引用

页码：235 / 253

页数：19

共 278 条

[51] Drug-sensitive FGFR2 mutations in endometrial carcinoma [J].

Dutt, Amit ;

Salvesen, Helga B. ;

Chent, Tzu-Hsiu ;

Ramos, Alex H. ;

Onofrio, Robert C. ;

Hatton, Charlie ;

Nicoletti, Richard ;

Winckler, Wendy ;

Grewal, Rupinder ;

Hanna, Megan ;

Wyhs, Nicolas ;

Ziaugra, Liuda ;

Richter, Daniel J. ;

Trovik, Jone ;

Engelsen, Ingeborg B. ;

Stefansson, Ingunn M. ;

Fennell, Tim ;

Cibulskis, Kristian ;

Zody, Michael C. ;

Akslen, Lars A. ;

Gabriel, Stacey ;

Wong, Kwok-Kin ;

Sellers, William R. ;

Meyerson, Matthew ;

Greulich, Heidi .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (25) :8713-8717

[52] Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [J].

Eisen, T ;

Boshoff, C ;

Mak, I ;

Sapunar, F ;

Vaughan, MM ;

Pyle, L ;

Johnston, SRD ;

Ahern, R ;

Smith, IE ;

Gore, ME .

BRITISH JOURNAL OF CANCER, 2000, 82 (04) :812-817

[53] SURAMIN, AN ACTIVE-DRUG FOR PROSTATE-CANCER - INTERIM OBSERVATIONS IN A PHASE-I TRIAL [J].

EISENBERGER, MA ;

REYNO, LM ;

JODRELL, DI ;

SINIBALDI, VJ ;

TKACZUK, KH ;

SRIDHARA, R ;

ZUHOWSKI, EG ;

LOWITT, MH ;

JACOBS, SC ;

EGORIN, MJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (08) :611-621

[54] Effect of recombinant human keratinocyte growth factor (rHuKGF) on the immunopathogenesis of intestinal graft-vs.-host disease induced without a preconditioning regimen [J].

Ellison, CA ;

Natuik, SA ;

Fischer, JMM ;

McIntosh, AR ;

Scully, SA ;

Bow, EJ ;

Danilenko, DM ;

Hayglass, KT ;

Gartner, JG .

JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (02) :197-211

[55] Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis [J].

Ellman, Michael B. ;

An, Howard S. ;

Muddasani, Prasuna ;

Im, Hee-Jeong .

GENE, 2008, 420 (01) :82-89

[56] Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors [J].

Ellsworth, JL ;

Berry, J ;

Bukowski, T ;

Claus, J ;

Feldhaus, A ;

Holderman, S ;

Holdren, MS ;

Lum, KD ;

Moore, EE ;

Raymond, F ;

Ren, HP ;

Shea, P ;

Sprecher, C ;

Storey, H ;

Thompson, DL ;

Waggie, K ;

Yao, L ;

Fernandes, RJ ;

Eyre, DR ;

Hughes, SD .

OSTEOARTHRITIS AND CARTILAGE, 2002, 10 (04) :308-320

[57] Dysregulation of the fibroblast growth factor system in major depression [J].

Evans, SJ ;

Choudary, PV ;

Neal, CR ;

Li, JZ ;

Vawter, MP ;

Tomita, H ;

Lopez, JF ;

Thompson, RC ;

Meng, F ;

Stead, JD ;

Walsh, DM ;

Myers, RM ;

Bunney, WE ;

Watson, SJ ;

Jones, EG ;

Akil, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (43) :15506-15511

[58] Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice [J].

Falardeau, John ;

Chung, Wilson C. J. ;

Beenken, Andrew ;

Raivio, Taneli ;

Plummer, Lacey ;

Sidis, Yisrael ;

Jacobson-Dickman, Elka E. ;

Eliseenkova, Anna V. ;

Ma, Jinghong ;

Dvfyer, Andrew ;

Quinton, Richard ;

Na, Sandra ;

Hall, Janet E. ;

Huot, Celine ;

Alois, Natalie ;

Pearce, Simon H. S. ;

Cole, Lindsay W. ;

Hughes, Virginia ;

Mohammadi, Moosa ;

Tsai, Pei ;

Pitteloud, Nelly .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (08) :2822-2831

[59] REQUIREMENT OF FGF-4 FOR POSTIMPLANTATION MOUSE DEVELOPMENT [J].

FELDMAN, B ;

POUEYMIROU, W ;

PAPAIOANNOU, VE ;

DECHIARA, TM ;

GOLDFARB, M .

SCIENCE, 1995, 267 (5195) :246-249

[60]

Figg WD, 2001, CLIN CANCER RES, V7, P1888

← 1 2 3 4 5 6 7 8 9 10 →